ESMO25: Relacorilant shows sustained efficacy in PARP-exposed resistant ovarian cancer

Most recurrent ovarian cancer cases arise in patients previously treated with PARP inhibitors making these results noteworthy ...

Avacta presents first preclinical data from dual payload pre|CISION® medicines at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets

Avacta Therapeutics (AIM: AVCT, ‘Avacta’, ‘the Company’), a clinical stage biopharmaceutical company developing pre|CISION ®, a tumor-activated oncology delivery platform, today announced the ...
European Medical Journal

PARP Inhibitors Transform Prostate Cancer Treatment

Discover a study on PARP inhibitors in prostate cancer, revealing survival benefits for patients with BRCA1/2 alterations.

Experimental inhibitor reduces cell death in models of life-threatening skin reactions

A collaborative research group has developed a novel therapeutic candidate that may improve the prognosis of severe cutaneous ...
Medscape

Novel Drug With New Mechanism Promising for Parkinson’s Motor Fluctuations

Glovadalen, a novel D1 receptor positive allosteric modulator, is linked to improve OFF time in patients with Parkinson’s ...
BioWorld

Dual inhibitor of PARP1 and c-Met to overcome tumor chemoresistance

The enzyme PARP1 helps repair single-stranded DNA breaks, and its inhibition shows antitumor efficacy in ovarian, breast, prostate and pancreatic cancers involving mutations in BRCA1 or BRCA2. However ...